dymista Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Dymista, and when can generic versions of Dymista launch?
Dymista is a drug marketed by Mylan Speciality Lp and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-seven patent family members in twenty-seven countries.
The generic ingredient in DYMISTA is azelastine hydrochloride; fluticasone propionate. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride; fluticasone propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dymista
A generic version of dymista was approved as azelastine hydrochloride; fluticasone propionate by APOTEX on April 28th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for dymista?
- What are the global sales for dymista?
- What is Average Wholesale Price for dymista?
Summary for dymista
International Patents: | 57 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 4 |
Clinical Trials: | 13 |
Patent Applications: | 36 |
Drug Prices: | Drug price information for dymista |
Drug Sales Revenues: | Drug sales revenues for dymista |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for dymista |
What excipients (inactive ingredients) are in dymista? | dymista excipients list |
DailyMed Link: | dymista at DailyMed |
![dymista drug patent expirations Drug patent expirations by year for dymista](/p/graph/s/t/dymista-patent-expirations.png)
![Drug Prices for dymista](/p/graph/drug-price/dymista.png)
![Drug Sales Revenue Trends for dymista](/p/graph/drug-sales-revenues/dymista.png)
Recent Clinical Trials for dymista
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Humanis Saglık Anonim Sirketi | Phase 1 |
St. Paul's Sinus Centre | Phase 4 |
MEDA Pharma GmbH & Co. KG | Phase 4 |
Pharmacology for dymista
Drug Class | Corticosteroid Histamine-1 Receptor Antagonist |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists Histamine H1 Receptor Antagonists |
Paragraph IV (Patent) Challenges for DYMISTA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
DYMISTA | Nasal Spray | azelastine hydrochloride; fluticasone propionate | 137 mcg/50 mcg per spray | 202236 | 1 | 2014-06-13 |
US Patents and Regulatory Information for dymista
dymista is protected by two US patents.
Patents protecting dymista
Combination of azelastine and steroids
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Combination of azelastine and steroids
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mylan Speciality Lp | DYMISTA | azelastine hydrochloride; fluticasone propionate | SPRAY, METERED;NASAL | 202236-001 | May 1, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Mylan Speciality Lp | DYMISTA | azelastine hydrochloride; fluticasone propionate | SPRAY, METERED;NASAL | 202236-001 | May 1, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for dymista
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mylan Speciality Lp | DYMISTA | azelastine hydrochloride; fluticasone propionate | SPRAY, METERED;NASAL | 202236-001 | May 1, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Mylan Speciality Lp | DYMISTA | azelastine hydrochloride; fluticasone propionate | SPRAY, METERED;NASAL | 202236-001 | May 1, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Mylan Speciality Lp | DYMISTA | azelastine hydrochloride; fluticasone propionate | SPRAY, METERED;NASAL | 202236-001 | May 1, 2012 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for dymista
See the table below for patents covering dymista around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Tunisia | SN04247 | COMBINATION OF AZELASTINE AND STEROIDS | ⤷ Sign Up |
Australia | 2009243420 | Combination of azelastine and steroids | ⤷ Sign Up |
Slovenia | 1519731 | ⤷ Sign Up | |
Georgia, Republic of | P20115143 | COMBINATION OF AZELASTINE AND FLUTICASONE | ⤷ Sign Up |
Brazil | 122014030158 | formulação farmacêutica | ⤷ Sign Up |
Brazil | PI0312128 | formulação farmacêutica compreendendo azelastina e éster de fluticasona | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for dymista
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1519731 | PA2013023 | Lithuania | ⤷ Sign Up | PRODUCT NAME: AZELASTINUM HYDROCHLORICUM + FLUTICASONUM PROPIONICUM; REGISTRATION NO/DATE: LT/1/13/3227/001 - LT/1 3/3227/004 |
1519731 | 40/2013 | Austria | ⤷ Sign Up | PRODUCT NAME: WIRKSTOFFKOMBINATION AUS AZELASTINHYDROCHLORID UND FLUTICASONPROPRIONAT; NAT. REGISTRATION NO/DATE: 1-31812 20130226; FIRST REGISTRATION: SK 24/0055/13-S 20130215 |
1519731 | C01519731/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: AZELASTIN + FLUTICASON; REGISTRATION NO/DATE: SWISSMEDIC 62675 06.05.2013 |
1519731 | 175 5006-2013 | Slovakia | ⤷ Sign Up | PRODUCT NAME: AZELASTIN ALEBO JEHO FARMACEUTICKY PRIJATE LNE SOLI A FARMACEUTICKY PRIJATEL NY ESTER FLUTIKAZONU; REGISTRATION NO/DATE: 24/0055/13-S 20130215 |
1519731 | CA 2013 00023 | Denmark | ⤷ Sign Up | PRODUCT NAME: AZELASTIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG EN FARMACEUTISK ACCEPTABEL ESTER AF FLUTICASON, HERUNDER AZELASTIN HYDROCHLORID OG FLUTICASON PROPIONAT; NAT. REG. NO/DATE: MT49785 20130219; FIRST REG. NO/DATE: SK 24/0055/13-S 20130215 |
1519731 | 92269 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |